-
Something wrong with this record ?
Prognostic value of posttreatment HPV-specific antibodies in patients with oropharyngeal tumors
S. Simonidesova, E. Hamsikova, V. Ludvikova, J. Klozar, O. Vencalek, R. Tachezy,
Language English Country United States
Document type Journal Article
Grant support
CZ.1.05/1.1.00/02.0109
Ministry of Education, Youth and Sports of the Czech Republic
No. LQ1604 (Project BIOCEV-FAR)
Ministry of Education, Youth and Sports of the Czech Republic
#17-28055A
Czech Health Research Council of the Ministry of Health of the Czech Republic
GAUK 114216
Granting Agency of Charles University in Prague
PubMed
30986340
DOI
10.1002/jso.25473
Knihovny.cz E-resources
- MeSH
- Time Factors MeSH
- Middle Aged MeSH
- Humans MeSH
- Human papillomavirus 16 immunology MeSH
- Survival Rate MeSH
- Oropharyngeal Neoplasms blood mortality therapy MeSH
- Follow-Up Studies MeSH
- Oncogene Proteins, Viral immunology MeSH
- Papillomavirus E7 Proteins immunology MeSH
- Predictive Value of Tests MeSH
- Prognosis MeSH
- Prospective Studies MeSH
- Antibodies, Viral blood MeSH
- Repressor Proteins immunology MeSH
- Neoplasms, Squamous Cell blood mortality therapy MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: The presence of human papillomavirus (HPV)-specific antibodies in patients with head and neck cancer at enrollment has prognostic significance. In cervical carcinoma patients, the decrease of HPV E6/E7-specific antibodies appears to be associated with a better prognosis. METHODS: This prospective study with follow-up focused on the persistence and prognostic value of antibodies specific for HR HPV-derived VLPs and HPV16 E6/E7 oncoproteins in patients with oropharyngeal cancers. In this study, we analyzed sera of 93 patients taken a year after the end of treatment and sera from 58 of these patients taken up to 14 years after treatment. RESULTS: The level of HPV-specific antibodies decreased on the 1-year follow-up and the decrease during the long follow-up was statistically significant. For HPV16 E7 antibodies the decrease was steeper in nonrecurrent patients. While the level of antibodies at enrollment was not predictive of recurrences, the decrease of HPV16 E6 antibodies at 1-year follow up was associated with better overall as well as disease-specific survival of patients. CONCLUSIONS: The data suggest that the pretreatment level of HPV-specific antibodies is not predictive of the occurrence of recurrences but the decrease HPV16 E6 antibodies on the 1-year follow-up is predictive of better survival of HN patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19034627
- 003
- CZ-PrNML
- 005
- 20191015104619.0
- 007
- ta
- 008
- 191007s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/jso.25473 $2 doi
- 035 __
- $a (PubMed)30986340
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Simonidesova, Simona $u Department of Otorhinolaryngology and Head and Neck Surgery, First Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic. Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 245 10
- $a Prognostic value of posttreatment HPV-specific antibodies in patients with oropharyngeal tumors / $c S. Simonidesova, E. Hamsikova, V. Ludvikova, J. Klozar, O. Vencalek, R. Tachezy,
- 520 9_
- $a BACKGROUND: The presence of human papillomavirus (HPV)-specific antibodies in patients with head and neck cancer at enrollment has prognostic significance. In cervical carcinoma patients, the decrease of HPV E6/E7-specific antibodies appears to be associated with a better prognosis. METHODS: This prospective study with follow-up focused on the persistence and prognostic value of antibodies specific for HR HPV-derived VLPs and HPV16 E6/E7 oncoproteins in patients with oropharyngeal cancers. In this study, we analyzed sera of 93 patients taken a year after the end of treatment and sera from 58 of these patients taken up to 14 years after treatment. RESULTS: The level of HPV-specific antibodies decreased on the 1-year follow-up and the decrease during the long follow-up was statistically significant. For HPV16 E7 antibodies the decrease was steeper in nonrecurrent patients. While the level of antibodies at enrollment was not predictive of recurrences, the decrease of HPV16 E6 antibodies at 1-year follow up was associated with better overall as well as disease-specific survival of patients. CONCLUSIONS: The data suggest that the pretreatment level of HPV-specific antibodies is not predictive of the occurrence of recurrences but the decrease HPV16 E6 antibodies on the 1-year follow-up is predictive of better survival of HN patients.
- 650 _2
- $a protilátky virové $x krev $7 D000914
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidský papilomavirus 16 $x imunologie $7 D052162
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a skvamocelulární nádory $x krev $x mortalita $x terapie $7 D018307
- 650 _2
- $a onkogenní proteiny virové $x imunologie $7 D009856
- 650 _2
- $a nádory orofaryngu $x krev $x mortalita $x terapie $7 D009959
- 650 _2
- $a Papillomavirus E7 - proteiny $x imunologie $7 D050725
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a represorové proteiny $x imunologie $7 D012097
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hamsikova, Eva $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Ludvikova, Viera $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Klozar, Jan $u Department of Otorhinolaryngology and Head and Neck Surgery, First Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic.
- 700 1_
- $a Vencalek, Ondrej $u Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science of the Palacky University in Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Tachezy, Ruth $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Průmyslová, Vestec, Czech Republic.
- 773 0_
- $w MED00010662 $t Journal of surgical oncology $x 1096-9098 $g Roč. 120, č. 2 (2019), s. 117-124
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30986340 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191015105044 $b ABA008
- 999 __
- $a ok $b bmc $g 1451287 $s 1073177
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 120 $c 2 $d 117-124 $e 20190415 $i 1096-9098 $m Journal of surgical oncology $n J Surg Oncol $x MED00010662
- GRA __
- $a CZ.1.05/1.1.00/02.0109 $p Ministry of Education, Youth and Sports of the Czech Republic
- GRA __
- $a No. LQ1604 (Project BIOCEV-FAR) $p Ministry of Education, Youth and Sports of the Czech Republic
- GRA __
- $a #17-28055A $p Czech Health Research Council of the Ministry of Health of the Czech Republic
- GRA __
- $a GAUK 114216 $p Granting Agency of Charles University in Prague
- LZP __
- $a Pubmed-20191007
